Conjugate · 25 amino acids

Adipotide studies and research data

PepBank has 1 Adipotide study with results. It gave Adipotide, with 5 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 5 results and 4 papers. Newer studies from Europe PMC

Results in people

0% of 5 results

Results in animals

100% of 5 results

Results in lab cells

0% of 5 results

From computer models

0% of 5 results

The molecule

Adipotide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Adipotide combines an adipose vascular targeting segment with a proapoptotic D-peptide. The identity overview gives a two-glycine linker. Exact-product disulfide connectivity remains unresolved. Related targeting constructs and the reduced PubChem form remain separate. AdisInsight reports Phase I development and discontinuation in 2019. FDA and EMA searches identified no approved product.

Kind: Conjugate · 25 residues
Development: Phase 1Ablaris Therapeutics and University of Texas M. D. Anderson Cancer CenterAdisInsight reports Phase I development and discontinuation in January 2019. Its latest information update is 18 January 2019. Current activity remains unresolved. No trial record or study was read. Source (opens in a new tab)

Targets

No molecular target is recorded for this peptide.

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

25 amino acids · 1 modification

CKGGRAKDCG

GLAKLAKKL

AKLAK

Properties

From identity sources

No formula or molecular weight is listed for Adipotide.

Calculated from the sequence

pKa set

Average mass: 2,557.20 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 2,555.5243 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 11.02; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 7.79; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.464; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Extinction coefficient, 280 nm (all Cys as cystines): 125 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: −0.90; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 82.4; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.32 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.780; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 11.02Bjellqvist (ExPASy) 10.24IPC peptide 10.75IPC protein 9.36

D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 11.02 · Net charge at pH 7.4: 7.79

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	10.00
1	10.00
2	9.96
3	9.69
4	8.73
5	8.11
6	8.00
7	7.91
8	7.31
9	5.64
10	4.00
11	0.07
12	−2.76
13	−3.71
14	−3.96

Composition

Hydrophobic36% (9)A L
Positive36% (9)K R
Negative4% (1)D
Special24% (6)C G

25 residues. Each residue counts in one class; F and W count as aromatic.

A Ala5 · 20%

I Ile0 · 0%

L Leu4 · 16%

M Met0 · 0%

V Val0 · 0%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys8 · 32%

R Arg1 · 4%

D Asp1 · 4%

E Glu0 · 0%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys2 · 8%

G Gly4 · 16%

P Pro0 · 0%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.399
μH, best 11-residue window: 0.780
Arrow direction: 141°
Residues: 25 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	C	0°	0.29
2	K	100°	-1.50
3	G	200°	0.48
4	G	300°	0.48
5	R	40°	-2.53
6	A	140°	0.62
7	K	240°	-1.50
8	D	340°	-0.90
9	C	80°	0.29
10	G	180°	0.48
11	G	280°	0.48
12	K	20°	-1.50
13	L	120°	1.06
14	A	220°	0.62
15	K	320°	-1.50
16	L	60°	1.06
17	A	160°	0.62
18	K	260°	-1.50
19	K	0°	-1.50
20	L	100°	1.06
21	A	200°	0.62
22	K	300°	-1.50
23	L	40°	1.06
24	A	140°	0.62
25	K	240°	-1.50

Results by area

Adipotide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

1 of 4 studies has results (25%), published 2011. Top row: every study. Bottom row: studies with results about Adipotide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies4 in all, 2011 to 2025

Studies with results1 in all, 2011

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Adipotide studies on weight and appetite

2 results · people 0 · animals 2 · lab 0

2 results

In monkeys, imaging showed less white fat after adipotide treatment.Science translational medicine, 2011
In monkeys, adipotide reduced body weight.Science translational medicine, 2011

Adipotide studies on blood sugar

1 result · people 0 · animals 1 · lab 0

1 result

In monkeys, adipotide improved insulin resistance.Science translational medicine, 2011

Adipotide studies on kidneys and bladder

1 result · people 0 · animals 1 · lab 0

1 result

In monkeys, adipotide changed kidney tubule function, and the changes were reversible.Science translational medicine, 2011

Adipotide studies on receptors and cell signals

1 result · people 0 · animals 1 · lab 0

1 result

In monkeys, adipotide induced cell death in white fat blood vessels.Science translational medicine, 2011

Trials and papers

Adipotide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

1 trial match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (1 of 1)

1 trial · 1 stopped early

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20122014201620182020

Ph 1
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
NCT01262664
24 May 2012 to 2 Jan 2019
Terminated
Terminated

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 1NCT01262664

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

M.D. Anderson Cancer Centern = 424 May 2012 to 2 Jan 2019

Prostate Cancer

Trial page ClinicalTrials.govUpdated 4 Jan 2019

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

4 studies match. Retracted studies are left out.

Showing 2 of 4 studiesquery qry_928b0e373425272fce00d32d

Studies with results

1 study

Animal study (in vivo) · old world monkeys · 2011

5 results

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Barnhart et al. 2011Science translational medicinecited by 77

PMID 22072637PMC3666164DOI 10.1126/scitranslmed.3002621PUB-22072637

Rights unknown5 results where Adipotide was given

Source link See results (5)

More studies

1 study

PubMed tag: none · 2012

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

Criscione et al. 2012Science translational medicinecited by 1

PMID 22539771DOI 10.1126/scitranslmed.3003760PUB-22539771

Full text at the publisher

Publisher page

No result for Adipotide (2 studies on this page)

These studies name Adipotide but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Comparative Study · 2013

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

Hossen et al. 2013Journal of controlled release : official journal of the Controlled Release Societycited by 43

PMID 23871959DOI 10.1016/j.jconrel.2013.07.013PUB-23871959

Rights unknown

Source link

PubMed tag: none · 2025

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity.

Chan et al. 2025Journal of the American Chemical Society

PMID 40591817DOI 10.1021/jacs.5c05536PUB-40591817

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Adipotide studies: 1 paper with results

Page 1 of 1

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.
Barnhart KF · Science translational medicine · 2011
Animal study (in vivo) · old world monkeys · 5 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The FDA approval API returned no matches for adipotide, prohibitin, TP01 or FTPP. This search does not prove worldwide absence of approval.	13 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	No matching active substance in the EMA central medicines data file. National authorisations are not covered.	13 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S0) Adipotide is not named on the accessible WADA list page.	2026 List	wada-ama.org (opens in a new tab)
Russia	Note	National medicine registration not established in this profile.	13 Oct 2026	Not recorded

Safety outcomes

1 safety result for Adipotide.

No safety results from studies in people

The safety results below come from animal or lab studies. They do not show what happens in people.

Animal evidence· 1

In monkeys from three species, adipotide produced predictable and reversible changes in renal proximal tubule function.
Animal study (in vivo)Old World monkeys

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000062
Peptide version: 5
Peptide hash: 546412b207f9ee52…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256633
22 Oct 2026UpdatedData version 254484
21 Oct 2026UpdatedData version 213590
14 Oct 2026UpdatedData version 212200
14 Oct 2026CreatedData version 198196

For developers

curl -s https://pepbank.io/v1/briefs/adipotide

Evidence summary for Adipotide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Body compositionMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Body weightMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Glycemic controlMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Kidney functionKidney and urinary	No results	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	1
Receptor activity and mechanismMetabolic and weight	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Body compositionMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Body weightMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Glycemic controlMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
Kidney functionKidney and urinary	No results	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	1
Receptor activity and mechanismMetabolic and weight	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Adipotide studies and research data

Adipotide identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

Helical wheel

Adipotide results by year and outcome

What the studies measured

Adipotide studies on weight and appetite

Adipotide studies on blood sugar

Adipotide studies on kidneys and bladder

Adipotide studies on receptors and cell signals

Adipotide trials

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Papers

Studies with results

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

More studies

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity.

Newer studies

Adipotide studies: 1 paper with results

Regulatory and safety

Animal evidence· 1

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

Adipotide results by year and outcome

Adipotide studies on weight and appetite

Adipotide studies on blood sugar

Adipotide studies on kidneys and bladder

Adipotide studies on receptors and cell signals

Adipotide trials

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Papers

Studies with results

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

More studies

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity.

Adipotide studies: 1 paper with results

Regulatory and safety

Animal evidence· 1

Doses studied

Data and API

Peptide

Latest changes

For developers